DUBLIN, IRELAND, April 13, 2026
SynOx Therapeutics has announced positive topline results from its pivotal Phase 3 TANGENT study, highlighting the potential of emactuzumab as a next-generation therapy for Tenosynovial Giant Cell Tumor (TGCT), a rare and debilitating condition affecting joints and mobility. The study demonstrated statistically significant improvements in tumor response, functional outcomes, and patient-reported measures, reinforcing the therapy’s differentiated profile in the evolving oncology and rare disease treatment landscape.
Phase 3 Results Demonstrate Strong Clinical Efficacy
The global, randomized, double-blind, placebo-controlled Phase 3 TANGENT trial met both primary and secondary endpoints with high statistical significance, including Objective Response Rate (ORR) and Tumor Volume Score (TVS) at six months. Patients receiving emactuzumab experienced rapid tumor reduction along with meaningful improvements in physical function, pain, stiffness, and range of motion, indicating a strong clinical benefit in managing TGCT. Importantly, these outcomes were supported by patient-reported measures such as PROMIS-PF, underscoring the therapy’s real-world functional impact.
Short-Course Therapy Offers Durable Benefits
A key differentiator of emactuzumab is its short-course treatment regimen, consisting of five doses administered over eight weeks. Despite this limited exposure, the therapy demonstrated durable and sustained clinical benefits, addressing one of the major limitations of existing chronic treatment options. This approach has the potential to reduce long-term treatment burden and improve patient compliance, particularly in a disease that significantly affects quality of life. The findings suggest that short-duration targeted therapies may represent a paradigm shift in TGCT management.
Advertisement
Favorable Safety Profile and Regulatory Pathway
Emactuzumab exhibited a manageable safety profile consistent with prior clinical studies, making it a promising candidate for broader clinical adoption. Given the chronic and non-lethal nature of TGCT, tolerability remains a critical factor, and the therapy’s safety profile supports its positioning as a viable alternative to long-term treatments. Based on these results, SynOx Therapeutics plans to submit a Biologics License Application (BLA) to the U.S. FDA in the second half of 2026, followed by a Marketing Authorization Application (MAA) in Europe, marking an important step toward commercialization.
Advancing Treatment Options for Rare Joint Tumors
TGCT is a rare, locally aggressive tumor affecting synovial joints, often leading to pain, stiffness, and reduced mobility, significantly impacting patients’ daily lives. Current treatment options, including surgery and long-term oral therapies, are associated with high recurrence rates and chronic treatment burden. Emactuzumab, a CSF-1R-targeting monoclonal antibody, is designed to reduce tumor-promoting macrophages and inflammation, offering a targeted and potentially more effective therapeutic strategy. The Phase 3 results reinforce its potential to transform the treatment landscape for TGCT patients.
The positive Phase 3 TANGENT study results position emactuzumab as a promising next-generation biologic therapy with the potential to address significant unmet needs in TGCT. With strong efficacy, durable benefits, and a manageable safety profile, the therapy represents a meaningful advancement in rare disease treatment. As SynOx moves toward regulatory submission, the findings highlight the growing importance of targeted biologics and short-course treatment strategies in modern bio-pharmaceutical innovation.
Source: SynOx Therapeutics press release
